Login to MyKarger

New to MyKarger? Click here to sign up.



Login with Facebook

Forgot your password?

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login
(Shibboleth or Open Athens)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Clinical Study

Association between Helicobacter pylori Infection and Pancreatic Cancer

Raderer M.a · Wrba F.c · Kornek G.a · Maca T.b · Koller D.Y.d · Weinlaender G.a · Hejna M.a · Scheithauer W.a

Author affiliations

Departments of a Internal Medicine I, b Internal Medicine II, and c Department of Clinical Pathology, d Department of Pediatrics, Vienna University Medical School, Vienna, Austria

Related Articles for ""

Oncology 1998;55:16–19

Do you have an account?

Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



Login Information





Contact Information










I have read the Karger Terms and Conditions and agree.



To view the fulltext, please log in

To view the pdf, please log in

Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.
Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00


Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Published online: December 12, 1997
Issue release date: January – February

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 1

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL

Abstract

Purpose: In order to determine whether infection with Helicobacter pylori might be associated with pancreatic adenocarcinoma, we performed a study to compare the H. pylori seroprevalence rate between patients with pancreatic carcinoma and matched control subjects. Patients and Methods: Blood samples from 92 patients with histologically confirmed diagnosis of pancreatic adenocarcinoma admitted to our hospital between January 1994 and July 1995 were analyzed for the presence of IgG antibodies against H. pylori by a commercially available enzyme-linked immunosorbent assay. Thirty patients with gastric cancer, 35 patients with colorectal cancer, and 27 healthy volunteers served as controls. In addition to these serological analyses, tumor specimens from 20 patients with pancreatic adenocarcinoma were microscopically investigated for the presence of H. pylori. Results: 65% of pancreatic cancer patients and 69% of those with gastric cancer were found to be seropositive, while only 45% of the other controls tested positive. Statistical analysis revealed no difference in seropositivity between the cohort of patients suffering from pancreatic and gastric cancer. The rate of seropositivity was more prominent, however, in pancreatic cancer patients when compared with those suffering from colorectal cancer combined with normal controls (p = 0.035), with an odds ratio of 2.1 (1.1–4.1). Microscopic evaluation of human pancreatic cancer specimens showed no evidence for the presence of H. pylori. Conclusion: Our data suggest an association between H. pylori infection and pancreatic cancer. Despite demonstration of a positive relationship and its physiological plausibility, larger prospective studies are needed to confirm our preliminary findings and to assess H. pylori as a potential carcinogenic risk factor.


References

  1. Brennan MF, Kinsella TJ, Casper ES: Cancer of the pancreas; in De Vita V, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology. Philadelphia, Lippincott 1993, pp 849–877.
  2. Warshaw AL, Fernandez-del Castillo C: Pancreatic carcinoma. N Engl J Med 1992;326:455–465.
  3. Vutuc C: Krebsmortalität und Krebsinzidenz; in Pirker R, Fiegl M, Huber (eds): Klinische Onkologie. Wien, Facultas, 1996, pp 13–19.
  4. National Cancer Institute: Annual cancer statistics review 1973–1988 (NIH publication No. 91-2789). Bethesda, Department of Health and Human Services, 1991.
  5. Friedman GD, van den Eeden SK: Risk factors for pancreatic cancer: An exploratory study. Int J Epidemiol 1993;22:30–37.
    External Resources
  6. Farrow DC, Davis S: Risk of pancreatic cancer in relation to medical history and the use of tobacco, alcohol, coffee and diet. Int J Cancer 1990;45:816–820.
  7. Ghadirian P, Simard A, Baillargeon J: Tobacco, alcohol and coffee and cancer of the pancreas. A population-based case control study in Quebec, Canada. Cancer 1991;67:2664–2670.
  8. Silverman DT, Dunn JA, Hoover RN, Schiffman M, Lillemoe KD, Schoenberg JB, Brown LM, Greenberg RS, Hayes RB, Swanson GM, Wacholder S, Schwartz AG, Liff JM, Pottern LM: Cigarette smoking and pancreas cancer: A case-control study based on direct interviews. J Natl Cancer Inst 1994;86:1510–1516.
    External Resources
  9. Birt DF, Stepan KR, Pour PM: Interaction of dietary fat and protein on pancreatic carcinogenesis in Syrian golden hamsters. J Natl Cancer Inst 1983;71:355–360.
    External Resources
  10. Gordis L: Consumption of methylxanthine-containing beverages and risk of pancreatic cancer. Cancer Lett 1990;52:1–12.
    External Resources
  11. Howe GR, Jain M, Miller AB: Dietary factors and risk of pancreatic cancer: Results of a Canadian population-based case-control study. Int J Cancer 1990;45:604–608.
    External Resources
  12. Offerhaus GJA, Tersmette AC, Tersmette KWF, Tytgat GNJ, Hoedemaker PJ, Vandenbroucke JP: Gastric, pancreatic and colorectal carcinogenesis following remote peptide ulcer surgery. Mod Pathol 1988;352–356.
  13. Smith JP, Solomon TE, Bagheri S, Kramer S: Cholecystokinin stimulates growth of human pancreatic adenocarcinoma SW-1990. Dig Dis Sci 1990;35:1377–1384.
  14. Taylor PR, Dowling RH, Palmer TJ, Hanley TC, Murphy GM, Mason RC, McColl I: Induction of pancreatic tumours by long-term duodenogastric reflux. Gut 1989;30:1596–1600.
    External Resources
  15. Marshall BJ: Helicobacter pylori. Am J Gastroenterol 1994;89:116–128.
  16. Parsonnet J, Friedman GD, Vandersteen DP: Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991;325:1127–1131.
  17. The EUROGAST Study Group: An association between Helicobacter pylori infection and gastric cancer: An international study. Lancet 1993;341:1359–1362.
  18. Wotherspoon AC, Ortiz-Hidalgo C, Falzon ME, Isaacson PG: Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175–1176.
  19. Hussell T, Isaacson PG, Crabtree JE, Spencer J: Cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993;342:571–574.
  20. Nightingale TE, Gruber J: Helicobacter and human cancer. J Natl Cancer Inst 1994;86:1505–1509.
    External Resources
  21. Ward JM, Fox JG, Anver MR, Haines DC, George CV, Collins MJ, Gorelick PL, Nagishima K, Gonda MA, Gilden RV, Tully JG, Russell RJ, Benveniste RE, Paster BJ, Dewhirst FE, Donovan JC, Anderson LM, Rice JM: Chronic active hepatitis and associated liver tumors in mice caused by a persistent bacterial infection with a novel Helicobacter species. J Natl Cancer Inst 1994;86:1222–1227.
  22. Talley NJ, Kost L, Haddad A, Zinsmeister AR: Comparison of commercial serological tests for detection of Helicobacter pylori antibodies. J Clin Microbiol 1992;30:3146–3150.
    External Resources
  23. The EUROGAST Study Group: Epidemiology of, and risk factors for, Helicobacter pylori infection among 3,194 asymptomatic subjects in 17 populations. Gut 1993;34:1672–1676.
  24. Megraud F: Epidemiology of Helicobacter pylori infection. Gastroenterol Clin North Am 1993;22:73–88.
  25. Talley NJ, Zinsmeister AR, Weaver A, DiMagno EP, Carpenter HA, Perez-Perez GI, Blaser MJ: Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst 1991;83:1734–1739.
  26. Lin JT, Wang JT, Wang TH, Wu MS, Chen CJ: Helicobacter pylori infection in early and advanced gastric cancer: A seroprevalence study in 143 Taiwanese patients. Hepatogastroenterology 1993;40:596–599.
  27. Moss SF, Neugut AI, Garbowski GC, Wang S, Treat M, Forde KA: Helicobacter pylori seroprevalence and colorectal neoplasia: Evidence against an association. J Natl Cancer Inst 1995;87:762–763.
  28. Jiang SJ, Liu WZ, Zhang DZ, et al: Campylobacter-like organisms in chronic gastritis, peptic ulcer, and gastric carcinoma. Scand J Gastroenterol 1987;22:553–558.
  29. Correa P: Human gastric carcinogenesis: A multistep and multifactorial process – First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735–6740.
  30. Brenes F, Ruiz B, Correa P, Hunter F, Rhamakrishnan T, Fontham E, Shi TY: Helicobacter pylori causes hyperproliferation of the gastric epithelium: Pre- and post-eradication indices of proliferating cell nuclear antigen. Am J Gastroenterol 1993;88:1870–1875.
  31. Correa P: Is gastric carcinoma an infectious disease? N Engl J Med 1991;325:1170–1171.
  32. Levi S, Beardshall K, Swift I, Foulkes W, Playford R, Ghosh P, Calam J: Antral Helicobacter pylori, hypergastrinemia, and duodenal ulcers: Effect of eradicating the organism. BMJ 1989;299:1504–1505.
  33. Graham DY, Opekum A, Lew GM, Evans DJ Jr, Klein PD, Evans DG: Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection. Am J Gastroenterol 1990;85:394–398.
    External Resources
  34. Moss SF, Legon S, Bishop AE, Polak JM, Calam J: Effect of Helicobacter pylori on gastric somatostatin in duodenal ulcer disease. Lancet 1992;340:930–932.
  35. Johnson LR: Effects of gastrointestinal hormones on pancreatic growth. Cancer 1983;47:1640–1645.
  36. Dembinski AB, Johnson LR: Stimulation of pancreatic growth by secretin, caerulein and pentagastrin. Endocrinology 1980;106:323–328.
  37. Townsend CM, Franklin RB, Watson LC, Glass EJ, Thompson JC: Stimulation of pancreatic cancer growth by caerulein and secretin. Surg Forum 1981;32:228–229.
  38. Fuchs CS, Mayer RJ: Gastric carcinoma. N Engl J Med 1995;333:4127–4132.
  39. Bateson MC: Cigarette smoking and Helicobacter pylori infection. Postgrad Med J 1993;69:41–44.
  40. Office of Population Censuses and Surveys: Classification of Occupations. London, Government Statistical Services, 1980.

Article / Publication Details

First-Page Preview
Abstract of Clinical Study

Published online: December 12, 1997
Issue release date: January – February

Number of Print Pages: 4
Number of Figures: 0
Number of Tables: 1

ISSN: 0030-2414 (Print)
eISSN: 1423-0232 (Online)

For additional information: https://www.karger.com/OCL


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.